Business Wire

Merz Aesthetics® Announces Salma Hayek Pinault as First-Ever Global Brand Ambassador for Ultherapy PRIME, the Next Generation Platform for Nonsurgical Skin Lifting and Tightening Treatments

Share

Marking Salma Hayek Pinault’s first aesthetics collaboration, the new Ultherapy PRIME campaign aims to set a new standard for the future of beauty and self-care, celebrating the transformative power of personalized, non-invasive skin lifting and tightening.

Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, is proud to announce world-renowned actress, director and producer, Salma Hayek Pinault, as the first-ever global brand ambassador for Ultherapy PRIME.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250409655489/en/

Redefining the future in medical aesthetics, Ultherapy PRIME is an advanced micro-focused ultrasound platform for personalized, non-invasive skin lifting and tightening.1,2 It is intended to lift and sculpt the skin of the upper face, lower face, neck and décolleté.1 It takes just one session, has no downtime, and delivers results that can last up to a year or more.1-3

With her unwavering commitment to authenticity, Salma Hayek Pinault trusts Ultherapy PRIME for a personalized, natural-looking lift, with results that can last up to a year or more .1-3 This collaboration reflects a shared belief in empowering individuals to look and feel their best to fuel confidence worldwide.

Salma Hayek Pinault is a highly acclaimed, Academy Award-nominated actress and Emmy-winning director, also celebrated for her work as a producer. She passionately advocates for causes that align with her core values and beliefs and has long supported several leading nonprofit organizations. As a strong advocate for authentic self-expression and looking great at any age, she encourages others to embrace treatments that enhance their natural features.

“Self-care is essential. Years on screen have taught me to embrace my journey and seek treatments that enhance my natural beauty,” said Salma Hayek Pinault. “Ultherapy PRIME boosts my production of collagen and elastin exactly where I need it*, giving me a long-lasting**, natural-looking lift. It's noninvasive, takes only one session, and has zero downtime. It is the future of beauty, and that’s why I can't stop talking about it."1-3,6

The Ultherapy PRIME platform is the evolution of Ultherapy® which has been recognized as the Gold Standard in non-invasive skin lifting and tightening.2 Built on Ultherapy®’s legacy of proven, natural-looking results, Ultherapy PRIMEredefines the future of nonsurgical skin lifting and tightening by uniquely combining an advanced micro-focused ultrasound platform with vivid real-time imaging.1 These advancements promote a safer and more effective, personalized lift that can last up to a year or more, paired with younger-looking skin.1-5

Since its September 2024 launch, Ultherapy PRIME has already been cleared in over 80% of our targeted markets, with more approvals expected in 2025.***

"We are proud and excited about the recent launch of Ultherapy PRIME, our next-generation platform for non-invasive skin lifting and tightening and a testament to our unwavering commitment to delivering meaningful innovations to our customers," said Bob Rhatigan, CEO of Merz Aesthetics®. "As we continue to expand the global footprint of this launch, we are thrilled to collaborate with Salma Hayek Pinault as the first-ever global brand ambassador for Ultherapy PRIME. At Merz Aesthetics® we empower individuals to embrace their unique beauty with confidence, and our collaboration with Salma Hayek Pinault compellingly embodies this purpose.”

To learn more and find a provider near you, visit Ultherapy.com. Follow @Ultherapy on Instagram for the latest news from Ultherapy PRIME and Hayek Pinault.

About Merz Aesthetics®

Merz Aesthetics® is a medical aesthetics business with a long history of empowering health care professionals, patients, and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves – however they define it. Clinically proven, its product portfolio includes injectables and devices designed to meet each patient’s needs Being family owned for more than 115 years, Merz Aesthetics® is known for building unique connections with customers who feel like family. Merz Aesthetics®’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

About Ultherapy®

The noninvasive Ultherapy® procedure is intended for dermatological sculpting and lifting of the dermis on the upper face, lower face, neck and décolleté. The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Reported adverse events from post-marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product information.

* The exact skin depth targeting occurs due to real-time visualization

**lasts up to a year or more

***Ultherapy PRIME is currently unavailable in China, India, Azerbaijan, Russia, Costa Rica, Dominican Republic, Guatemala, Mexico, Peru, Uruguay, Iraq, Israel, Jordan, Lebanon

References:

  1. Ulthera® Instructions for Use.
  2. Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
  3. Werschler WP, Werschler PS. Longterm efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
  4. Pavicic T, Ballard JR, Bykovskaya T, et al. Microfocused ultrasound with visualization: consensus on safety and review of energy-based devices. J Cosmet Dermatol. 2022;21(2):636-647.
  5. Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
  6. Marquardt K, Hartmann C, Wegener F, Park JY, Halbert D, Hsu S, Hengl T. Microfocused Ultrasound With Visualization Induces Remodeling of Collagen and Elastin Within the Skin. J Cosmet Dermatol. 2025 Jan;24(1):e16638

© 2025 Ulthera, Inc. All Rights Reserved. MERZ AESTHETICS® is a trademark and/or registered trademark of Merz Pharma GmbH & Co. KGaA in the U.S. and/or certain other countries. ULTHERA, ULTHERAPY, and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera, Inc. in the U.S. and/or certain other countries.

Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and international patents to which Ulthera, Inc. has rights are issued, published, or pending.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250409655489/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Qualcomm Announces Quarterly Cash Dividend18.4.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on June 26, 2025, to stockholders of record at the close of business on June 5, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business

Kinaxis Launches Tariff Response Solution to Help Supply Chains Adapt to Disruption with Confidence17.4.2025 19:30:00 CEST | Press release

New solution simulates tariff impacts, aligns teams, and enables action in under three weeks As ongoing tariff pressures and trade uncertainty continue to reshape global supply chains, Kinaxis® (TSX:KXS), the leader in real-time supply chain orchestration, today launched Kinaxis Tariff Response - a new offering that helps companies simulate tariff exposure, run strategic scenarios, and make data-informed decisions quickly. Built on the company’s AI-powered Maestro™ platform and delivered by Kinaxis supply chain experts, the service can be live in as few as 21 days, giving planners access to tariff modeling without the cost or complexity of building it internally. The solution meets rising demand for scenario planning - providing a faster, more accessible way for companies to shift from reactive firefighting to proactive orchestration. While AI-powered what-if scenario planning has long been a core capability of Maestro, Kinaxis Tariff Response builds on that foundation with a focused s

Rigaku and SPERA PHARMA Initiate Strategic Partnership to Advanced Pharmaceutical Development17.4.2025 17:00:00 CEST | Press release

Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc. (headquarters: Osaka; President & Representative Director: Keitaro Iwaki; hereinafter “SPERA PHARMA”) have initiated a strategic partnership aimed at accelerating and transforming pharmaceutical development by leveraging the two companies’ cutting-edge technologies and extensive expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417047994/en/ Left: Keitaro Iwaki, President & Representative Director, SPERA PHARMA; Right: Jun Kawakami, President & CEO, Rigaku SPERA PHARMA will use XtaLAB Synergy-ED, an integrated platform for electronic diffraction provided by Rigaku, for contract analytical services, thereby offering customers robust support in pharmaceutical development. The XtaLAB Synergy-ED incorporates 3D ED/MicroED1, which is utilized for the structu

CORRECTING and REPLACING MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine17.4.2025 15:36:00 CEST | Press release

MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive. Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom. Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars. Seventh paragraph, first sentence should read: Today, 8% of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technology (such as C-TAP terminals) as well as Smart POS devices which offer merchants digital tools and do more than just accept payments. (instead of MSP’s total processed transaction volume is handled through in-person payments, using traditional payment terminal technolo

MultiSafepay Supporting 20,000 SMEs to Scale Through Payment Integration and Digitisation with Antom Technology Engine17.4.2025 15:36:00 CEST | Press release

MultiSafepay, the Amsterdam-based digital payment provider, now serves 20,000+ SME merchants across Europe, with merchant numbers growing 11% since its strategic integration with Antom, empowering thousands of businesses to thrive. Transaction volumes have surged, growing by 44% YoY, driven organically by rapid deployment of POS solutions and collaboration with Antom. Ant International has opened a new office in Amsterdam’s City Centre for MultiSafepay which enables more efficient collaboration with Ant International’s other business pillars. MultiSafepay (MSP), an Amsterdam-based payment service provider, which became part of Ant International’s Antom, reported strong growth since its strategic integration with Antom, supporting thousands more SMEs in Europe to scale through innovative solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417858076/en/ Ant International’s new office in Amsterdam City Centre will hous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye